Feed

27/01/2023
Quantum com­put­ing pat­ent in­crease is far above av­er­age
On Wed­nes­day 25 Janu­ary 2023, the European Pat­ent Of­fice (EPO) is­sued their In­sight Re­port in­to quantum com­put­ing and pat­ents. In their Re­port, the EPO con­sidered quantum com­put­ing pat­ents in gen­er­al...
25/01/2023
CMS Green Globe | New coun­try ad­ded!
Stay in­formed about the latest sus­tain­ab­il­ity claims trends and de­vel­op­ments CMS Green Globe is an in­ter­act­ive plat­form that al­lows busi­nesses and cli­ents to stay aware and duly in­formed about all the main rap­idly chan­ging trends and de­vel­op­ments re­lated to sus­tain­ab­il­ity claims across the world.Here you will find in­form­a­tion on reg­u­la­tion and de­vel­op­ments you need to know when ad­vert­ising and mar­ket­ing your busi­ness or product by us­ing sus­tain­ab­il­ity claims as well as our key ex­perts to sup­port you in nav­ig­at­ing the world of such claims.CMS Green Globe helps you to avoid gre­en­wash­ing your con­sumer in your jur­is­dic­tion as well as across the globe. Dis­cov­er CMS Green Globe Best ex­plored on desktop
25/01/2023
Turk­ish 'Pres­id­ent’s De­cision on De­term­in­a­tion of Com­pan­ies Sub­ject to...
On 30 Novem­ber 2022, Tur­key pub­lished the Pres­id­ent’s De­cision on De­term­in­a­tion of Com­pan­ies Sub­ject to In­de­pend­ent Audit in the Of­fi­cial Gaz­ette, re­peal­ing the former De­cision on the De­term­in­a­tion...
25/01/2023
Key out­comes from COP-15
At the end of 2022, the 15th Con­fer­ence of Parties of the United Na­tions Con­ven­tion on Bio­lo­gic­al Di­versity cul­min­ated in a new Glob­al Biod­iversity Frame­work to 2030. Twenty three tar­gets re­quire broad...
24/01/2023
Data loc­al­isa­tion re­quire­ments in Turki­ye
The concept of data loc­al­isa­tion is not spe­cific­ally gov­erned un­der Turk­ish Data Pro­tec­tion Law (DPL) numbered 6698, but the DPL re­stricts per­son­al data trans­fers made abroad in such a man­ner that it...
18/01/2023
What is the sig­ni­fic­ance of a clin­ic­al tri­al pro­tocol as pri­or art at the...
The EPO Ap­peal Board has fur­ther re­fined their view on when pri­or art dis­clos­ures of clin­ic­al tri­al pro­to­cols are an is­sue for pat­entab­il­ity of med­ic­al use claims. De­cision T1806/18 In de­cision T1806/18...
16/01/2023
Use of out­sourced IT per­son­nel in Cent­ral and East­ern Europe
While Europe is the re­gion most im­pacted by the on­go­ing war in Ukraine, IT ser­vice mar­kets in Cent­ral and East­ern Europe (CEE) are ex­pec­ted to con­tin­ue to grow by nearly 6% and 7% in 2022 and 2023 re­spect­ively...
23/12/2022
EIOPA re­leases an­nu­al re­port on sanc­tions un­der IDD in 2021
On 20 Decem­ber, the European In­sur­ance and Oc­cu­pa­tion­al Pen­sions Au­thor­ity (EIOPA) re­leased the an­nu­al re­port on sanc­tions im­posed by na­tion­al com­pet­ent au­thor­it­ies un­der the In­sur­ance Dis­tri­bu­tion Dir­ect­ive...
19/12/2022
European Com­mis­sion’s green light to €14.3 mil­lion Croa­tian com­pens­a­tion...
The  Croa­tian  au­thor­it­ies,  which  we  as­sisted  in  the  pre­par­a­tion  of  the  file, no­ti­fied in Au­gust 2022 to the European Com­mis­sion, a meas­ure aimed at par­tially com­pens­at­ing the dam­age...
16/12/2022
Arm­chair in­ven­tions part 2:  Pre­lim­in­ary opin­ion on plaus­ib­il­ity at the...
The is­sue of plaus­ib­il­ity was pre­vi­ously re­ferred to the En­larged Board of Ap­peal (EBA), the highest ju­di­cial au­thor­ity at the European Pat­ent Of­fice (EPO). Our art­icle on the re­fer­ral can be found here...
12/12/2022
Glob­al Life Sci­ences & Health­care For­um 2022: Fa­cing the op­por­tun­it­ies...
Di­git­al ad­vances and in­nov­at­ive ther­apies are push­ing the bound­ar­ies of health and the leg­al world has to keep pace Life sci­ences are fizz­ing with in­genu­ity and in­nov­a­tion with re­volu­tion­ary gene and...
22/11/2022
Glob­al Life Sci­ences & Health­care For­um 2022: Life Sci­ences are reap­ing...
Di­git­al trans­form­a­tion in life sci­ences is cre­at­ing op­por­tun­it­ies to counter health­care’s most in­tract­able prob­lems from treat­ing rare dis­eases to ac­cel­er­at­ing dia­gnostics and re­du­cing treat­ment back­logs...